High-dose Furmonertinib in the Treatment in Patients With Advanced, Metastatic NSCLC With Progressed After First- or Second-line Treatment With Osimertinib
Clinical trial NCT06394674 · RECRUITING
Trial details
- NCT number
- NCT06394674
- Sponsor
- Changhai Hospital
- Status
- RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2024-05-01
- Primary completion
- 2025-06-01
- Enrollment
- 84
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.